Wellington Management Group LLP Sells 139,337 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Wellington Management Group LLP reduced its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 45.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 164,431 shares of the company's stock after selling 139,337 shares during the period. Wellington Management Group LLP owned about 0.49% of TransMedics Group worth $10,252,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Norges Bank purchased a new position in TransMedics Group in the 4th quarter worth approximately $22,861,000. Emerald Advisers LLC grew its stake in shares of TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock worth $23,176,000 after purchasing an additional 220,804 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after acquiring an additional 146,115 shares in the last quarter. State of Michigan Retirement System bought a new stake in TransMedics Group during the 4th quarter valued at approximately $6,734,000. Finally, Raymond James Financial Inc. purchased a new position in TransMedics Group during the fourth quarter valued at $3,845,000. Institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TMDX. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $122.70.

Remove Ads

TransMedics Group Trading Down 2.0 %

TMDX traded down $1.77 during trading hours on Tuesday, reaching $85.08. 477,510 shares of the company's stock traded hands, compared to its average volume of 1,332,106. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a 50-day moving average price of $71.19 and a 200 day moving average price of $80.67. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The firm has a market capitalization of $2.86 billion, a PE ratio of 90.63 and a beta of 2.14.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.